Patient identification algorithm and inclusion criteria
Table 1
Distribution of histology types and methods of treatment summary
| Histology | Number of patients |
|---|---|
| Squamous cell carcinoma | 37 (63.8%) |
| Adenoid cystic carcinoma | 9 (15.5%) |
| Microcellular carcinoma | 5 (8.6%) |
| Non-microcellular carcinoma | 4 (6.9%) |
| Adenocarcinoma | 2 (3.5%) |
| Papillary carcinoma | 1 (1.7%) |
| Methods of treatment | Number of patients |
| Radiotherapy | 25 |
| Radiotherapy + endoscopic resection | 10 |
| Radiotherapy + surgery | 4 |
| Radiotherapy + chemotherapy | 6 |
| Radiotherapy + endoscopic resection | |
| + chemotherapy | 3 |
| Endoscopic resection | 3 |
| Chemotherapy | 5 |
| Symptomatic | 2 |
Table 2
The characteristics of radiotherapy
| Number of patients | Total dose range (Gy2) | Median total dose (Gy2) | Mean total dose (Gy2) | SD (Gy2) | Fraction dose (Gy) | Median fraction dose (Gy) | Mean fraction dose (Gy) | |
|---|---|---|---|---|---|---|---|---|
| Radiotherapy | 48 | 14.0–82.6 | 33.2 | 45.0 | ±21.5 | 1.6–8.0 | 2.5 | 3.0 |
| Curative | 23 | |||||||
| External beam | 23 | 42.5–82.6 | 66.0 | 66.4 | ±8.8 | 1.6–3.0 | 2.0 | 2.0 |
| radiotherapy | ||||||||
| Brachytherapy boost | 3 | 12.5–16.0 | 16.0 | 14.8 | ±2.0 | 5.0–6.0 | 6.0 | 5.6 |
| 24 | 18.7–48.5 | 24.0 | 28.2 | ±7.4 | 2.0–8.0 | 4.0 | 3.7 | |
| Palliative | ||||||||
| External beam | ||||||||
| radiotherapy | 20 | 18.7–42.0 | 23.3 | 27.1 | ±5.7 | 2.0–4.0 | 4.0 | 3.4 |
| Brachytherapy | ||||||||
| 5 | 16.0–29.7 | 24.0 | 23.5 | ±4.9 | 6.0–8.0 | 6.0 | 6.6 |
Gy = doses converted to 2-Grey equivalent doses (EQD2) using linear-quadratic model
Overall survival of patients with adenoid cystic carcinoma (ACC) and squamous cell carcinoma (SCC).
Overall survival of patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, and 2.
Table 3
The characteristics of other cancers among patients with tracheal cancer (TC)
| Patient No | HP of TC | Year of diagnosis of TC | HP of the other cancer | Year of diagnosis of the other cancer |
|---|---|---|---|---|
| (1) | SCC | 2011 | Myelodysplastic syndrome | 2009 |
| (2) | SCC | 2006 | Larynx cancer - SCC | 1998 |
| (3) | SCC | 2005 | Clear cell renal carcinoma | 2005 |
| (4) | SCC | 2011 | Thyroid adenocarcinoma | 1978 |
| (5) | ACC | 2005 | Lung cancer - SCC | 2006 |
| (6) | Non-micro | 2013 | Clear cell renal carcinoma | 1995 |
| (7) | SCC | 2008 | Larynx cancer - SCC | 1999 |
| (8) | SCC | 1999 | Lung cancer - SCC | 1995 |
| (9) | SCC | 2003 | Larynx cancer - SCC | 2000 |
| (10) | Micro | 2010 | Prostate cancer - adenocarcinoma | 2008 |
| (11) | SCC | 2015 | Breast cancer - mucinous carcinoma | 2005 |
ACC = adenoid cystic carcinoma; HP = histopathological type; Micro = microcellular carcinoma; No = number; Non-micro = non-microcellular carcinoma; SCC = squamous cell carcinoma; TC = tracheal cancer
Overall survival in the irradiated (RT) and non-RT group.